Novartis AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novartis with three other
pharmaceutical manufacturers in Europe:
Roche Holding Aktiengesellschaft
(2018
sales of 56.85 billion Swiss Francs [US$57.13 billion]
of which 77%
was Pharmaceuticals),
GlaxoSmithKline plc
of the United Kingdom
(£30.82 billion [US$39.56 billion]
of which 56%
was Pharmaceuticals), and
Bayer AG
which is
based in Germany
(39.59 billion Euro [US$43.84 billion]
of which 42%
was Pharmaceuticals & Biological Products).
Sales Analysis.
Novartis reported sales of 51.94 billion Swiss Francs (US$52.20 billion)
for the
year ending
December of 2018.
This
represents
an
increase of 5.7%
versus 2017, when the company's sales were 49.16 billion Swiss Francs.
This was the third consecutive year of growth at Novartis.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Novartis had sales
of 54.36 billion Swiss Francs.
Sales of Alcon saw an increase
that was more than double the company's growth rate: sales were up
18.2% in 2018, from
5.91 billion Swiss Francs to 6.98 billion Swiss Francs.
Not all segments of Novartis experienced an increase in sales in 2018:
sales of Sandoz fell 2.4% to 9.63 billion Swiss Francs.